0.2566
3.73%
0.0076
Eterna Therapeutics Inc stock is traded at $0.2566, with a volume of 148.81K.
It is up +3.73% in the last 24 hours and down -44.82% over the past month.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
See More
Previous Close:
$0.249
Open:
$0.249
24h Volume:
148.81K
Relative Volume:
0.22
Market Cap:
$12.99M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0455
EPS:
-5.64
Net Cash Flow:
$-17.32M
1W Performance:
+4.36%
1M Performance:
-44.82%
6M Performance:
-85.49%
1Y Performance:
-86.89%
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Name
Eterna Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ERNA
Eterna Therapeutics Inc
|
0.2575 | 12.99M | 598.00K | -44.93M | -17.32M | -8.31 |
VRTX
Vertex Pharmaceuticals Inc
|
410.28 | 105.21B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
715.50 | 78.48B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
636.22 | 37.55B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
241.88 | 31.19B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
114.00 | 27.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eterna Therapeutics Inc Stock (ERNA) Latest News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online
Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada
Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire
Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan
ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa
Eterna Therapeutics initiates $1 million stock buyback - Investing.com India
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - GlobeNewswire
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges - Investing.com Australia
ERNA Stock Hits 52-Week Low at $0.52 Amid Market Challenges By Investing.com - Investing.com South Africa
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India
Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times
Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Business Wire
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK
NTN Buzztime Enters Into Material Definitive Agreement and Reports Voting Results at Annual Meeting Eterna Therapeutics Inc., a company listed on the Nasdaq Stock Market under the symbol ERNA, recently filed a Form 8-K with the Securities - Defense World
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire
Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa
Eterna Therapeutics announces share issuance and executive agreements - Investing.com India
Eterna, Factor announce license, collaboration agreement - Yahoo Finance
Eterna secures exclusive license for cell therapy tech - Investing.com India
Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire
Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World
Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks
Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com
Eterna Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):